| Document |
Document Title |
|
WO/2003/014296A2 |
Compounds containing a specific saturated or unsaturated branched chain terminal group; a polar leading group; and a long-chain aliphatic, non-cyclic, saturated or unsaturated, substituted or unsubstituted, hydrocarbon group linking them...
|
|
WO/2003/011210A2 |
There are provided novel compounds of formula (I), wherein R1, R2, R3, T, U, X, Y, V and W are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes...
|
|
WO/2003/011819A1 |
The present invention relates to a compound of the formula I: (Formula I) in which: A, B, R?1¿, Z, n and R?2¿ are as defined in Claim 1. These compounds are useful in the treatment of dyslipidaemia, atherosclerosis and diabetes.
|
|
WO/2003/010128A2 |
Perfluoroalkyl-substituted amines, acids, amino acids and thioether acid compounds containing a perfluoroalkyl-iodoalkyl or perfluoroalkyl-alkene group as well as derivatives thereof, are described. They are useful as surfactants in a va...
|
|
WO/2003/010148A1 |
The invention relates to novel pyrazoline derivatives of formula (I), in which R?1¿, R?2¿, R?3¿ and R?4¿ have the meanings as cited in the description, to a number of methods for producing these substances, to their use for controlli...
|
|
WO/2003/008372A1 |
A bactericide which contains as the active ingredient a diamine derivative represented by the formula (1): (1) wherein R1 to R7 each represents a specific substituent, e.g., C1−6 alkyl&semi and R8 represents optionally substituted aryl...
|
|
WO/2003/007954A2 |
The invention is directed to sulfonyl aromatic hydroxamic acid compounds and salts thereof that, inter alia, inhibit matrix metalloprotease (MMP) activity and/or aggrecanase activity. In some particularly preferred embodiments, the compo...
|
|
WO/2003/006424A1 |
The present invention relates to compounds of the general formula (I), wherein A is a non-aromatic ring system containing 4 to 8 carbon atoms, wherein the ring system comprises at least one double bond and wherein one or more of the carb...
|
|
WO/2003/006021A1 |
The present invention relates to compounds of formula (I): Useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's...
|
|
WO/2003/006013A1 |
The present invention relates to compounds of formula (I) useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the betasecretase enzyme that are useful in the treatment of Alzheimer's d...
|
|
WO/2003/006628A2 |
Disclosed are compounds that inhibit the microbial NAD synthetase enzyme. For example, disclosed are compounds of the formula Ar¿1?-X-Ar¿2?-Y-L-Z-Q, wherein Q is Q¿1?Ar¿3? or Ar¿3?Q¿1?; Ar¿1?, Ar¿2?, and Ar¿3? are independently ...
|
|
WO/2003/006423A1 |
Disclosed are compounds of the formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the betasecretase enzyme that are useful in the treatment of Alzeheimer's disease and ot...
|
|
WO/2003/004479A1 |
The present invention pertains to compounds of the formula (1), which are, inter alia, antiproliferative agents, anticancer agents, antimycobacterial agents, antituberculosis agents, and/or thioredoxin/thioredoxin reductase inhibitors: w...
|
|
WO/2003/004458A1 |
The present invention relates to 2-(benzoylamino)benzoic acid derivatives of the formula (I), wherein the variants Ar, X and R are described in the specification. The said compounds modulate the activity of peroxisome proliferator-activa...
|
|
WO2002070467B1 |
The invention relates to new diphenylurea having the formula (I) or a salt thereof, where Y is CO=O, C=S, C=NH, (C=O)2 or SO2; and to processes for the preparation of these compounds and to their use in the treatment of protozoal disease...
|
|
WO/2003/005025A1 |
The present invention relates to a method for identifying compounds capable of binding the ligand binding domain of peroxisome proliferator-activated receptor gamma (PPAR$g(g)), and selectively modulating the activity of PPAR$g(g). The s...
|
|
WO/2003/003012A1 |
The present invention provides a method for identifying a protein capable of binding to a specific target molecule. The method involves allowing candidate proteins to bind to the target molecule in the presence of a second molecule which...
|
|
WO/2002/103340A2 |
A piezoelectric crystal element and a sensor utilizing the same are presented for use in a sensor device for identifying at least one foreign material from environment. The crystal element comprises at least one crystal resonator in the ...
|
|
WO2002082185B1 |
A photoacid compound having general structure: R-O(CF2)nSO3X wherein n is an integer between about 1 to 4; R is selected from the group consisting of: substituted or unsubstituted C1-C12 linear or branched alkyl or alkenyl, substituted o...
|
|
WO/2002/102389A1 |
The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the gener...
|
|
WO/2002/100295A2 |
Facially amphiphilic polymers and articles made therefrom having biocidal surfaces are disclosed. The polymers can inhibit the growth of microorganisms in contact with the surface or in areas adjacent to said biocidal surface. There is a...
|
|
WO/2002/100339A2 |
The present invention relates to a new process for the synthesis of racemic and optically active bicalutamide starting from ethyl pyruvate and methyl methacrylate. The present invention discloses processes of preparing bicalutamide inter...
|
|
WO/2002/100812A1 |
A medicine containing as the active ingredient a novel carboxylic acid derivative useful as an insulin resistance ameliorant. The carboxylic acid derivative is represented by the following general formula (I). Also provided are a salt or...
|
|
WO/2002/100824A1 |
The present invention is to provide a novel colchicine derivative represented by the formula (I) with halogen or nitric ester group, or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same as effecti...
|
|
WO/2002/100341A2 |
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
|
|
WO/2002/100344A2 |
This invention is directed to compounds that provide for sustained systemic concentrations of GABA analogs following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using su...
|
|
WO/2002/100392A1 |
The present invention provides an extended release oral dosage form of prodrugs of gabapentin and other GABA analogs, which dosage forms exhibit reduced toxicity. The dosage forms are particularly useful in administering those prodrugs o...
|
|
WO/2002/100903A1 |
Compounds of the formulae I, II, and III wherein R¿1? is for example hydrogen, C¿3?-C¿8? cycloalkyl, C¿1?-C¿12?alkyl, phenyl unsubstituted or substituted; R¿2? and R¿2?' for example are hydrogen, C¿1?-C¿20?alkyl, C¿3?-C¿8?cycl...
|
|
WO/2002/100172A1 |
The invention provides methods of screening agents, conjugates or conjugate moieties, linked or linkable to agents, for capacity to be transported as substrates through the PEPT2 transporter. The invention also provides methods of treatm...
|
|
WO/2002/100347A2 |
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA anal...
|
|
WO/2002/100818A2 |
The present invention relates to compounds of formula useful in treating Alzheimer's disease and other similar disease. These compounds include inhibitors of the betasecretase enzyme that are useful in the treatment of Alzheimer's diseas...
|
|
WO/2002/100850A1 |
A process for preparation of heterocyclic compounds represented by the general formula (I), characterized by cyclizing an acetal (II) or an aldehyde (III) in the presence of a phosphoric acid compound in a molar amount below that of the ...
|
|
WO/2002/098559A2 |
An organoaluminum reaction product of A.) a ligand of the formula I, wherein R¿1? represents an alkyl, aryl, arylalkyl, or alkylaryl group, a C¿3-24? silyl group, or hydrogen, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, R¿7?, R¿12?, and R¿13...
|
|
WO/2002/098849A2 |
Disclosed are compounds of formula X, where R¿n?, R¿20?, R¿1?, R¿2?, R¿3?, and R¿c? are defined herein. These compounds are useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions comprising c...
|
|
WO/2002/098846A1 |
The present invention provides certain sulfonamide derivatives of formula (I) (in which the variables are as defined in the claims) useful for potentiating glutamate receptor function in a patient and therefore useful for treating a wide...
|
|
WO/2002/098848A1 |
The present invention provides antitumor compounds of the formula(I), and antitumor methods.
|
|
WO/2002/098406A1 |
The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making
|
|
WO/2002/098241A1 |
Flavour and fragrance compositions comprising 1-mercapto-1-arylalkanes or derivatives thereof according to formula (I).
|
|
WO/2002/096864A1 |
The invention relates to carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments, physiologically-acceptable salts and physiologically-functional derivatives thereof. Compounds of formula (I), in w...
|
|
WO/2002/096866A2 |
The present invention relates to thiolalkyl benzoic acids of the Formulae (Ia), (Ib) and (I) (in which the variables are as defined in the claims), pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of...
|
|
WO/2002/096850A1 |
The present invention refers to compounds of formula (I) as precursors for a ketone of formula (II), an aldehyde or ketone of formula (III), and an aldehyde or ketone of formula (IV). These compounds are useful in perfumery, especially i...
|
|
WO/2002/096901A2 |
The invention relates to 1,3-dihydroxybenzene derivatives of general formula (I) or (Ia), or the physiologically acceptable, water-soluble salts thereof, R'1 representing a substituted pyridyl group, a pyrimidyl group, or a radical of fo...
|
|
WO/2002/094764A1 |
The present invention ralates to compounds of formula (I): wherein R is hydrogen (H) or c¿1-6? alkyl; and X is defined such that - NH - (X) - COOH is the residue of an amino acid, which amino acid may itself optionally be substituted at...
|
|
WO/2002/094742A1 |
The present invention relates to a cost effective and industrially advantageous process for the preparation of amorphous cilastatin sodium.
|
|
WO/2002/094771A1 |
A process for the production of an organic sulphur-containing product which comprises reacting a sulphur-containing compound with an unsaturated hydrocarbon in the presence of a boron compound at a temperature of less than or equal to 50...
|
|
WO/2002/094766A1 |
A phthalamide derivative represented by the general formula (I): (I) (wherein R1 and R2 may be the same or different and each represents hydrogen, C1−6 alkyl, etc.&semi R3 represents halogeno, cyano, etc.&semi R4 represents halogeno, C...
|
|
WO/2002/094765A2 |
The present invention provides a substituted anilide derivative of formula (I): (I) (II) (III) {wherein Z is a group of formula (II) or (III) (in these formulas, A is C¿1?-C¿6? alkylene, C¿2?-C¿6? alkenylene, etc., R?1¿ is H, haloge...
|
|
WO/2002/092024A2 |
Enzymes mediating in the release of compounds characteristic of human malodour and in particular axillary malodour, and compounds that inhibit said enzymes having general formula (I).
|
|
WO/2002/092552A2 |
The invention relates to compounds of the general Formula (I), wherein R3, R4, R5, R6, R7, R8, Ar2, Q1, Q2, a, b and n have the significances given in claim 1, and optionally the enantioners thereof. The active ingredients have advantage...
|
|
WO/2002/092553A1 |
This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels a...
|
